The Exchange had sought clarification from Alkem Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
NSE sought clarification from Alkem Laboratories regarding discrepancies in their XBRL format financial results for Q4 FY20225 (quarter ended 31st March 2025). The issue was that the company had marked the quarterly results as 'audited' in the XBRL filing, which appeared to be incorrect classification. The company has now submitted revised XBRL files (both Standalone and Consolidated) to correct this technical discrepancy. This was a routine compliance clarification handled administratively between the company and the exchange.
This is a minor administrative correction with no material impact on the company's financials or operations. The corrected filing has been resubmitted to the exchange for their records.